Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study

HIGHLIGHTS

• who: Takahiro Wakasaki et al. from the Editor:, University of Nebraska Kitakyushu, Japan have published the research: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study, in the Journal: PLOS ONE of 15/Nov/2021
• what: The authors increased the number of patients from the previous report, and this study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) with or without Cmab after exposure to ICIs affected by prior cetuximab use . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.